Aramchol, a novel partial inhibitor of SCD1, has been proved as a promising therapy for nonalcoholic steatohepatitis (NASH) and led to no severe adverse events in a phase 2b clinical trial, compared with other SCD1 inhibitors42. This evidence concerns the gene SCD and metabolic dysfunction-associated steatohepatitis.